Trial Profile
Phase II study to evaluate the efficacy of NGX 426 in patients with acute migraine
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 31 Oct 2007
Price :
$35
*
At a glance
- Drugs Dasolampanel (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Sponsors TorreyPines Therapeutics Inc
- 31 Oct 2007 New trial record.